B-CELL NON HODGKIN LYMPHOMA
Clinical trials for B-CELL NON HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new B-CELL NON HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for B-CELL NON HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for tough lymphoma
Disease control OngoingThis study tests a new treatment for people with relapsed or hard-to-treat B-cell non-Hodgkin lymphoma. It combines two therapies: a bispecific antibody and CAR-T cells, aiming to improve effectiveness. The study will check safety and how well the treatment controls the cancer. A…
Matched conditions: B-CELL NON HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 17, 2026 04:38 UTC
-
Lymphoma study pulled: N-803 after CAR t therapy never got off the ground
Disease control TerminatedThis study aimed to see if the drug N-803 is safe and tolerable when given as a maintenance therapy after CAR T-cell treatment in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. It was designed for adults who had already received CAR T therapy and achieved at le…
Matched conditions: B-CELL NON HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated May 17, 2026 04:37 UTC
-
New drug cocktail aims to stop lymphoma relapse after powerful treatments
Disease control OngoingThis study tests whether combining two drugs, pembrolizumab and tazemetostat, can help prevent aggressive B-cell non-Hodgkin lymphoma from coming back after a stem cell transplant or CAR T-cell therapy. About 32 adults who have already had or are about to have one of these treatm…
Matched conditions: B-CELL NON HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated May 17, 2026 04:35 UTC
-
New combo therapy aims to boost CAR T-Cell power against lymphoma
Disease control OngoingThis early-phase study tests whether adding the drug acalabrutinib to CAR T-cell therapy (axicabtagene ciloleucel) is safe and works better for people with certain B-cell lymphomas. About 23 adults whose cancer has not responded to prior treatments will receive the combination. T…
Matched conditions: B-CELL NON HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
Can a simple drug tame CAR-T's dangerous side effects?
Disease control OngoingThis study tests whether the drug anakinra can prevent or reverse severe side effects from CAR-T cell therapy, a powerful cancer treatment. About 62 adults with certain B-cell cancers (like leukemia or lymphoma) will receive anakinra alongside their CAR-T cells. The goal is to re…
Matched conditions: B-CELL NON HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 07, 2026 18:43 UTC
-
Blood test may predict lymphoma outcomes without scans
Knowledge-focused OngoingThis study looks at whether tracking tumor DNA in the blood (ctDNA) can help predict how well treatment works for people with B-cell non-Hodgkin lymphoma. Researchers will collect blood samples from 60 patients before and during treatment to see if changes in ctDNA levels match w…
Matched conditions: B-CELL NON HODGKIN LYMPHOMA
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated May 13, 2026 16:03 UTC
-
Blood test may outsmart scans in spotting lymphoma return
Knowledge-focused OngoingThis study looks at whether a simple blood test can find signs of lymphoma coming back after chemotherapy, possibly before CT scans do. About 500 adults with aggressive B-cell Non-Hodgkin lymphoma will give blood samples after treatment. The goal is to see if this test could repl…
Matched conditions: B-CELL NON HODGKIN LYMPHOMA
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated May 04, 2026 16:22 UTC